Skip to main content

Jeffs’ Brands: Fort Technology Launches AI-Powered Pest Control App on Android, Completing Cross-Platform Rollout

Tel Aviv, Israel, Oct. 16, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that its majority-owned subsidiary, Fort Technology Inc. (“Fort”) (TSXV: FORT), has officially launched its innovative artificial intelligence (“AI”)-powered pest control mobile application, the Fort app, on the Google Play Store. Following the successful debut on the Apple App Store earlier this year, the Android launch marks the completion of Fort’s cross-platform rollout and another key step in Jeffs’ Brands’ strategy to expand its direct-to-consumer digital presence. The Fort app for Android is available for download here. The Fort app empowers users to easily identify household pests using AI and offers customized...

Continue reading

Form 8.3 – [IQE PLC – 15 10 2025] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IQE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Supplement to the notice of the Extraordinary General Meeting issued on 1 October 2025

On 1 October 2025, the notice of an extraordinary general meeting, to be held on 23 October 2025, was issued. The notice specifies that the proposal concerning the election of board members, including deputy chairmen, under item 1 of the agenda will be published subsequently. In continuation thereof, it is announced that Niels Konstantin Jensen, David Mark Stanton and Janis Carol Kong will resign from the board of directors effective as of 23 October 2025. The full proposal concerning item 1 of the agenda is set out below:          It is proposed that Anne Louise Eberhard, Birgit Otto, Anne Skovbro, Henrik Dam Kristensen and Michael Holm are elected as new members of the board of directors. Further, it is proposed that Anne Louise Eberhard and current member of the board of directors, Lars Sandahl Sørensen, are elected as new deputy chairmen. Lars...

Continue reading

Atos Group awarded EcoVadis Platinum Medal for its commitment to sustainability for the 6th year in a row

               Atos Group awarded EcoVadis Platinum Medal for its commitment to sustainability for the 6th year in a row Paris, France, October 16, 2025 – Atos Group, a global leader of AI-powered digital transformation, announces today it has once again been awarded the coveted EcoVadis Platinum Medal for its Corporate Social Responsibility (CSR) performance, with an improved score of 84 out of 100. This recognition places Atos in the top 1% of companies assessed by EcoVadis in its industry (Computer programming, consultancy and related activities). Since its founding in 2007, EcoVadis has grown into a globally trusted provider of business sustainability ratings with a network of more than 150,000 rated companies. EcoVadis evaluates across four categories: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. Atos...

Continue reading

RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases

APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) — RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, to help identify novel biomarkers that enable earlier detection and more precise monitoring of systemic, neurodegenerative, and retinal diseases. By integrating RetinalGenix’s non-invasive retinal imaging platform with Seer Bio’s advanced proteomic profiling, RetinalGenix aims to uncover molecular and cellular signatures associated with disease onset, progression, and risk—often before clinical symptoms appear. The collaboration targets a range of critical conditions, including Alzheimer’s...

Continue reading

Commodity trade faces geopolitical turbulence, Willis reports

LONDON, Oct. 16, 2025 (GLOBE NEWSWIRE) — Commodity traders are facing renewed geopolitical risks as military conflicts proliferate, tariffs increase, and global supply chains come under pressure, although these challenges could drive volatility-driven profits for some players, according to a new report from by Willis, a WTW business (NASDAQ: WTW), Managing the new economic risks in commodity trading. Recent market volatility in response to US tariff threats against China highlight the report’s central question: whether commodity giants are prepared to navigate unpredictable deglobalization pressures. To explore this, Willis and Oxford Analytica consulted an international panel of senior external-affairs and risk leaders, producing a global risk radar and risk-by-risk synthesis of how leading global commodity traders view these...

Continue reading

Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference

VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new preclinical data from its ATR inhibitor program will be presented in a poster session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22-26 at the Hynes Convention Center Boston, Massachusetts. DNA damage repair (DDR) enzymes, including Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR), are crucial for maintaining stability in cells. Inhibition of DDR enzymes has proven to be a compelling therapeutic option for numerous cancer indications. However, they lack the ability to effectively...

Continue reading

Humanoid Global Reports Progress on Cartwheel Robotics’ Flagship Humanoid Yogi

Vancouver, BC & Reno, Nevada, Oct. 16, 2025 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, announces an update from Cartwheel Robotics Inc. (“Cartwheel Robotics”). Cartwheel Robotics is developing “Yogi,” an embodied AI platform designed to move naturally, respond intuitively, and bring a lifelike, approachable presence to everyday environments. Built with medical-grade silicone and protective soft materials for comfort and safety, Yogi combines precision-engineered high-torque actuators with overload protection and a modular, swappable battery system, enabling reliable and extended daily operation. “Cartwheel...

Continue reading

Share Buyback Transaction Details October 9 – October 15, 2025

PRESS RELEASE                                         Share Buyback Transaction Details October 9 – October 15, 2025 Alphen aan den Rijn – October 16, 2025 – Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 379,400 of its own ordinary shares in the period from October 9, 2025, up to and including October 15, 2025, for €41.8 million and at an average share price of €110.12. These repurchases are part of the share buyback program announced on February 26, 2025, under which we intend to repurchase shares for €1 billion during 2025. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2025Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2025...

Continue reading

Ekspress Grupp’s subsidiary Delfi Latvia facing contractual dispute regarding advertising sales

AS Ekspress Grupp informs that its Latvian subsidiary AS Delfi has received notice that SIA Ekis & Co-Positioning and Consulting has filed an insolvency application against Delfi in relation to a contractual dispute over advertising services in news portal LA.lv.  Ekspress Grupp wishes to clarify that this is a standard commercial dispute regarding contested invoices that should be resolved through normal legal channels, not through insolvency proceedings. Delfi Latvia has legitimate concerns and has requested verification of calculation methods used for invoicing.   The amount of the claim in question is 200,000 euros. The dispute has no impact on Delfi Latvia’s everyday operations and this matter has no material impact on the financial position or operations of Delfi Latvia or the broader Ekspress Grupp. The management is taking...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.